Carti Cancer Center in Little Rock, Ark, has installed Toshiba America Medical Systems’ Infinix 4D CT system, making it the first healthcare facility in the United States to do so. The Infinix 4D, which amalgamates Toshiba’s Infinix-i angiography system with its Aquilion One Vision Edition CT system, helps clinicians improve visualization and workflow.
By utilizing the system in an interventional radiology and oncology environment, Carti is able to plan, treat, and verify tumors in a single setting. Further, real CT imaging available on demand may help interventionalists improve visualization of tumors and feeder vessels, in addition to providing whole-organ body perfusion. During hepatoma embolizations, for instance, interventionalists can immediately confirm that treatment is hitting the right areas with CT, as well as identify feeder vessels—thus enabling them to guide catheters into the vessels via the angiography system’s 3D roadmap.
“Interventional radiology and oncology is born from innovation, and technology advancements like the Infinix 4D CT create exciting new possibilities and prepare us for the future of care,” says David Hays, MD, director of Carti’s diagnostic and interventional radiology department. “For today’s patients, the system makes procedures that were difficult to perform and turns them into manageable cases that are easier, faster, and more accurate.”
Due to the system’s Aquilion One Vision Edition capabilities, the Infinix 4D is also capable of capturing an entire organ in one rotation with 640 slices and 16 cm of anatomical coverage. And Toshiba officials say the combination of the interventional lab and CT eliminates the need to transfer patients between departments and helps clinicians promote patient safety. Also promoting patient safety, they say, is the company’s Adaptive Iterative Dose Reduction 3D technology for CT systems, as well as the Infinix’s radiation-dose-tracking abilities.
For more information about this product, visit Toshiba America Medical Systems.
Amazing technology, right ?